Details of the Drug

General Information of Drug (ID: DM5U3IF)

Drug Name
KB-004
Synonyms Anti-EphA3 tyrosine kinase receptor monoclonal antibody (Humaneered, iv, cancer), KaloBios
Indication
Disease Entry ICD 11 Status REF
Haematological malignancy 2B33.Y Phase 1/2 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
D0FJ9W

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Ephrin type-A receptor 3 (EPHA3) TTHS2LR EPHA3_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01211691) Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Kalobios.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47.
5 Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46.
6 Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8.